Every 8-K that Immuneering Corporation (IMRX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IMRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IMRX filings page.
Immuneering Corporation reported second-quarter 2026 results and progress across its oncology pipeline. In a single-arm Phase 2a study in first-line pancreatic cancer, atebimetinib plus modified gemcitabine/nab-paclitaxel showed a 17.3 month median overall survival in 55 patients, with 84% of evaluable patients weight stable or gaining at three months and limited high-grade treatment-related adverse events. A pivotal global Phase 3 MAPKeeper 301 trial in first-line metastatic pancreatic cancer is now dosing patients at more than 30 sites, supported by new peer-reviewed data in Cancer Research describing atebimetinib’s mechanism and preclinical activity.
Cash, cash equivalents and marketable securities totaled $182.7 million as of June 30, 2026, and the company expects its cash runway to extend into 2029. Second-quarter R&D expenses were $14.0 million and G&A expenses were $5.0 million. Net loss attributable to common stockholders was $17.3 million, or $0.27 per share. The company also appointed Andrew Gengos as Chief Financial Officer and outlined additional trials and preclinical milestones through 2028.
Immuneering Corporation is appointing Andrew Gengos as Chief Financial Officer, Treasurer and principal financial officer, effective when he starts work, expected on or before July 16, 2026. Current Senior Vice President Finance and Chief Accounting Officer Mallory Morales will remain the company’s principal accounting officer.
Gengos will receive an annual base salary of $530,000 and be eligible for a target annual bonus equal to 40% of base salary, based on Board-set objectives. As a material inducement to join, he is expected to receive an option to purchase 650,000 shares of common stock under the 2025 Employment Inducement Award Plan, contingent on his start date.
If terminated without cause or he resigns for good reason, he is eligible for 12 months of base salary continuation, any earned prior-year bonus, and up to 12 months of subsidized COBRA. After a qualifying change in control, he may instead receive similar salary and COBRA benefits, an additional payment equal to 1.0x his target bonus, and accelerated vesting of specified equity awards.
Immuneering Corporation held its Annual Meeting of Stockholders on June 11, 2026, where stockholders voted on director elections and the auditor appointment. A total of 44,495,059 Class A common shares were present in person or by proxy, representing approximately 68.8 percent of shares outstanding as of the April 15, 2026 record date.
Stockholders elected Peter Feinberg and Laurie B. Keating as Class II directors to serve until the 2029 Annual Meeting, with 26,420,287 and 27,121,501 votes for their election, respectively, and no votes against. Stockholders also approved the ratification of RSM US LLP as the independent registered public accounting firm for the year ending December 31, 2026, with 42,142,848 votes for and 1,920,218 against.
Immuneering Corporation reported updated Phase 2a results for its oral MEK inhibitor atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer. As of the April 24, 2026 cutoff, median overall survival in the 320 mg intent-to-treat group of 55 patients was 17.3 months, compared with an 8.5‑month median overall survival reported for the standard of care from the MPACT trial.
Median progression-free survival in this group was 8.3 months. Among 50 response‑evaluable patients, overall response rate was 36% and disease control rate was 82%. In patients with sufficient data, 84% maintained or gained weight relative to baseline.
The combination was generally well tolerated, with Grade ≥3 anemia in 16% of patients and neutropenia in 18%, and no Grade 5 treatment‑emergent adverse events. Immuneering outlined plans to start a pivotal Phase 3 MAPKeeper 301 trial in mid‑2026 with topline data expected in mid‑2028, along with additional lung cancer and preclinical programs through 2027.
Immuneering Corporation reported first-quarter 2026 results and highlighted progress in its oncology pipeline. The company ended March 31, 2026 with $198.6 million in cash, cash equivalents and marketable securities and expects this to fund operations into 2029.
R&D expenses were $10.6 million and G&A expenses were $4.7 million. Net loss attributable to common stockholders was $13.5 million, or $0.21 per share, compared with $15.0 million, or $0.42 per share, a year earlier.
Clinically, new survival data from 55 first-line pancreatic cancer patients treated with atebimetinib plus mGnP will be presented in an oral session at the 2026 ASCO Annual Meeting. The pivotal Phase 3 MAPKeeper 301 trial in first-line metastatic pancreatic cancer is now recruiting, and a Phase 2 lung cancer trial is planned to start dosing in the second half of 2026. The company also reported a third-line pancreatic cancer patient on atebimetinib monotherapy with 27 months progression-free survival and an ongoing 85% tumor burden reduction.
Immuneering Corporation reported fourth-quarter and full-year 2025 results alongside major clinical progress for its lead cancer drug candidate, atebimetinib. In an ongoing Phase 2a trial in first-line pancreatic cancer, atebimetinib plus mGnP showed 64% overall survival at 12 months, compared with a 35% standard-of-care benchmark for GnP.
The company finished 2025 with $217 million in cash, cash equivalents and marketable securities and expects its cash runway to extend into 2029. Fourth-quarter 2025 research and development expenses fell to $9.3 million from $14.9 million a year earlier, while general and administrative expenses rose to $4.5 million. Net loss narrowed to $11.6 million, or $0.18 per share, from $18.1 million, or $0.58 per share.
Immuneering plans to start dosing in its pivotal Phase 3 MAPKeeper 301 trial in first-line metastatic pancreatic cancer in mid-2026 and initiate a Phase 2 lung cancer trial of atebimetinib plus Libtayo in the second half of 2026.
Immuneering Corporation reported updated interim results from its ongoing Phase 2a trial of atebimetinib, an oral MEK inhibitor, combined with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer. In the initial intent-to-treat group of 34 patients treated at 320 mg once daily, 12‑month overall survival was 64% as of a December 15, 2025 cutoff, compared with 35% reported for standard of care in the MPACT trial. Median overall survival has not yet been reached, and median progression-free survival was 8.5 months.
Six‑ and nine‑month overall survival in this group was 94% and 83%, respectively, versus 67% at six months and an estimated ~47% at nine months for standard of care, based on MPACT data and company extrapolations. The combination was generally well tolerated, with Grade ≥3 treatment-emergent adverse events of anemia and neutropenia each in 18% of patients, no Grade 5 events, and no new safety signals. Immuneering outlined plans in 2026 to present additional circulating tumor DNA data, provide updated survival data from over 50 first-line pancreatic cancer patients, start a pivotal Phase 3 trial in first-line pancreatic cancer, and begin a trial with atebimetinib plus Libtayo in non-small cell lung cancer.
Immuneering Corporation announced its financial results for the quarter ended September 30, 2025 and shared operational updates. The details are contained in a press release dated November 12, 2025, which is provided as an exhibit and treated as furnished rather than filed under securities laws.
Immuneering Corporation entered into an underwriting agreement to sell 18,959,914 shares of its Class A common stock at $9.23 per share in a public offering under an effective shelf registration, with underwriters holding a 30-day option to buy up to 2,843,987 additional shares. All shares are being sold by the company.
Concurrently, Immuneering agreed to a $25.0 million private placement with Aventis Inc., a Sanofi subsidiary, under which Aventis will purchase 2,708,559 Class A shares at the same price, contingent on the closing of the public offering. The company expects net proceeds of about $164.1 million from the offering and $23.3 million from the private placement, to fund preclinical and clinical development, working capital, and general corporate purposes.
Immuneering states that its cash, cash equivalents, marketable securities and these net proceeds should fund operations into 2029. In connection with the deal, it reduced the capacity of its existing $100,000,000 at-the-market program by $1,250,007 to $98,749,993 and suspended sales under that ATM amount.
Immuneering Corp (IMRX) reported safety and clinical development plans for atebimetinib in an 8-K filed September 24, 2025. In the 320 mg ITT population, treatment-emergent adverse events (TEAEs) occurring in <10% of patients included fatigue (6%), vomiting (3%), febrile neutropenia (3%), hypokalemia (3%) and nausea (3%). No Grade 5 TEAEs or new safety signals were identified.
The company expects regulatory feedback on pivotal Phase 3 trial plans in Q4 2025 and plans to announce updated overall survival (OS) and progression-free survival (PFS) data from 34 first-line pancreatic cancer patients treated with atebimetinib plus mGnP, including presentation at a 2026 scientific conference. Subject to regulatory feedback, Immuneering aims to initiate a pivotal Phase 3 trial by end-2025 and dose the first patient by mid-2026, and may add additional combination arms in 2026, including non-small cell lung cancer.
Immuneering Corporation announced its financial results for the quarter ended June 30, 2025 and provided operational updates, and the company furnished the full press release as Exhibit 99.1 to this Current Report. The 8-K itself does not contain the detailed financial figures or operational text; those details are included in the attached press release.
The filing explicitly states that the information is furnished, not filed, meaning it is not subject to Section 18 liabilities of the Exchange Act and is not incorporated by reference into other filings except by specific reference. This document serves as a formal vehicle to make the quarter-end results and operational commentary publicly available, while the substantive metrics and narrative are contained in the exhibit.